Women's experiences with oral and vaginal pre-exposure prophylaxis: The VOICE-C qualitative study in Johannesburg, South Africa

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Van Der Straten, Ariane ^a,b   Stadler, Jonathan ^c   Montgomery, Elizabeth ^a   Hartmann, Miriam ^a   Magazi, Busiswe ^c   Mathebula, Florence ^c   Schwartz, Katie ^d   Laborde, Nicole ^a   Soto Torres, Lydia ^e  

^a RTI INTERNATIONAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^d FAMILY HEALTH INTERNATIONAL   (United States)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; PLACEBO; TENOFOVIR; AGENTS USED INTRAVAGINALLY; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ARTHRALGIA; ARTICLE; ATTITUDE TO HEALTH; COHABITATION; CONCURRENT SEXUAL PARTNERSHIP; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG USE; ETHNOGRAPHIC RESEARCH; FEMALE; GASTROINTESTINAL DISEASE; GEL; HEARTBURN; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERVIEW; MEDICATION COMPLIANCE; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL (TOPIC); PRE EXPOSURE PROPHYLAXIS; PROPHYLAXIS; QUALITATIVE RESEARCH; RANDOMIZED CONTROLLED TRIAL; SOCIAL CLASS; SOCIAL INTERACTION; SOUTH AFRICA; TABLET; TRAVEL; WORK; HIV INFECTIONS; INFORMATION PROCESSING; MIDDLE AGED; PRE-EXPOSURE PROPHYLAXIS; THEORETICAL MODEL; YOUNG ADULT;

ADULT; ANTI-HIV AGENTS; FEMALE; FOCUS GROUPS; HIV INFECTIONS; HUMANS; MEDICATION ADHERENCE; MIDDLE AGED; MODELS, THEORETICAL; PRE-EXPOSURE PROPHYLAXIS; QUALITATIVE RESEARCH; SOUTH AFRICA; VAGINAL CREAMS, FOAMS, AND JELLIES; WOMEN; YOUNG ADULT;

EID: 84896127057     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0089118     Document Type: Article

References (60)

1. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, et al. (2012) Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women. N Engl J Med doi:10.1056/NEJMoa1108524: 1-12.
2. Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, et al. (2012) Antiretroviral Preexposure Prophylaxis for Heterosexual HIV Transmission in Botswana. N Engl J Med doi:10.1056/NEJMoa1110711: 1-12.
3. Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, et al. (2013) Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. The Lancet 381: 2083-2090.
4. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, et al. (2010) Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. New Eng J Med 363: 2587-2599.
5. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, et al. (2010) Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329: 1168-1174.
6. Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, et al. (2012) Preexposure Prophylaxis for HIV Infection among African Women. N Engl J Med doi:10.1056/NEJMoa1202614: 1-12.
7. Marrazzo J, Ramjee G, Nair G, Palanee T, Mkhize B, et al. (2013) Pre-exposure prophylaxis for HIV in women: daily oral tenofovir, oral tenofoviremtricitabine, or vaginal tenofovir gel in the VOICE Study (MTN 003). CROI. Atlanta GA.
8. van der Straten A, Van Damme L, Haberer JE, Bangsberg DR (2012) Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention. AIDS 26: F13-19.
9. Baeten JM, Haberer JE, Liu AY, Sista N (2013) Preexposure Prophylaxis for HIV Prevention: Where Have We Been and Where Are We Going? J Acquir Immune Defic Syndr 63: S122-S129.
10. Ambia J, Agot K (2013) "Barriers and Facilitators of Adherence in User-Dependent HIV Prevention Trials, a Systematic Review". International STD Research & Reviews 1: 12-29.
11. Montgomery CM, Gafos M, Lees S, Morar NS, Mweemba O, et al. (2010) Re-framing microbicide acceptability: findings from the MDP301 trial. Culture, health & sexuality 12: 649-662.
12. Woodsong C, MacQueen K, Amico KR, Friedland B, Gafos M, et al. (2013) Microbicide clinical trial adherence: insights for introduction. Journal of the International AIDS Society 16.
13. Morrow K, Rosen R, Richter L, Emans A, Forbes A, et al. (2003) The acceptability of an investigational vaginal microbicide, PRO 2000 Gel, among women in a phase I clinical trial. J Womens Health (Larchmt) 12: 655-666. (Pubitemid 37266008)
14. Sahin-Hodoglugil NN, Montgomery E, Kacanek D, Morar N, Mtetwa S, et al. (2011) User experiences and acceptability attributes of the diaphragm and lubricant gel in an HIV prevention trial in southern Africa. AIDS Care 23: 1026-1034.
15. Montgomery CM, Lees S, Stadler J, Morar NS, Ssali A, et al. (2008) The role of partnership dynamics in determining the acceptability of condoms and microbicides. AIDS Care 20: 733-740. (Pubitemid 351913397)
16. Domanska CA, Teitelman AM (2012) Factors that affect acceptance of HIV microbicides among women. Collegian 19: 23-32.
17. Abdulai M, Baiden F, Adjei G, Afari-Asiedu S, Adjei K, et al. (2012) An assessment of the likely acceptability of vaginal microbicides for HIV prevention among women in rural Ghana. BMC Women's Health 12: 40.
18. Woodsong C, Alleman P (2008) Sexual pleasure, gender power and microbicide acceptability in Zimbabwe and Malawi. AIDS Educ Prev 20: 171-187. (Pubitemid 351679862)
19. Montgomery ET, Chidanyika A, Chipato T, van der Straten A (2012) Sharing the trousers: gender roles and relationships in an HIV-prevention trial in Zimbabwe. Culture, health & sexuality 10.1080/13691058.2012.697191: 1-16.
20. Martin Hilber A, Kenter E, Redmond S, Merten S, Bagnol B, et al. (2012) Vaginal practices as women's agency in Sub-Saharan Africa: A synthesis of meaning and motivation through meta-ethnography. Soc Sci Med 74: 1311-1323.
21. van der Straten A (2006) Intravaginal practices and diaphragm use in Zimbabwe (poster presentation); 23-26 April; Cape Town, South Africa.
22. Stadler J, Saethre E (2010) Rumours about blood and reimbursements in a microbicide gel trial. African Journal of AIDS Research 9: 345-353.
23. Saethre EJ, Stadler J (2010) Gelling medical knowledge: innovative pharmaceuticals, experience, and perceptions of efficacy. Anthropology and Medicine 17: 99-111.
24. Ware NC (2011) What's love got to do with it? - A relationship framework for research on adherence to Antiretroviral Therapy (ART) as pre-exposure prophylaxis. 6th International Conference on HIV Treatment and Prevention Adherence. Miami, Florida.
25. Van der Elst EM, Mbogua J, Operario D, Mutua G, Kuo C, et al. (2012) High acceptability of HIV pre-exposure prophylaxis but challenges in adherence and use: qualitative insights from a phase I trial of intermittent and daily PrEP in at-risk populations in Kenya. AIDS Behav: 1-11.
26. Montgomery CM, Pool R (2011) Critically engaging: integrating the social and the biomedical in international microbicides research. J Int AIDS Soc 14: S4.
27. Pool R, Montgomery CM, Morar NS, Mweemba O, Ssali A, et al. (2010) A mixed methods and triangulation model for increasing the accuracy of adherence and sexual behaviour data: the Microbicides Development Programme. PLoS One 5: e11600.
28. Pool R, Montgomery CM, Morar NS, Mweemba O, Ssali A, et al. (2010) Assessing the accuracy of adherence and sexual behaviour data in the MDP301 Vaginal Microbicides Trial using a mixed methods and triangulation model. PLoS One 5: e11632.
29. Minnis AM, Gandham S, Richardson BA, Guddera V, Chen B, et al. (2012) Adherence and acceptability in MTN 001: a randomized cross-over trial of daily oral and topical tenofovir for HIV prevention in women. AIDS Behav.
30. Montgomery E, van der Straten A, Cheng H, Wegner L, Masenga G, et al. (2012) Vaginal Ring Adherence in Sub-Saharan Africa: Expulsion, Removal, and Perfect Use. AIDS Behav 10.1007/s10461-012-0248-4: 1-12.
31. Montgomery ET, Woodsong C, Musara P, Cheng H, Chipato T, et al. (2010) An acceptability and safety study of the Duet® cervical barrier and gel delivery system in Zimbabwe. J Int AIDS Soc 13: 30.
32. Woodsong C, Alleman P, Musara P, Chandipwisa A, Chirenje M, et al. (2011) Preventive Misconception as a Motivation for Participation and Adherence in Microbicide Trials: Evidence from Female Participants and Male Partners in Malawi and Zimbabwe. AIDS Behav: 1-6.
33. Larios SE, Lozada R, Strathdee SA, Semple SJ, Roesch S, et al. (2009) An exploration of contextual factors that influence HIV risk in female sex workers in Mexico: The Social Ecological Model applied to HIV risk behaviors. AIDS Care 21: 1335-1342.
34. Latkin CA, Knowlton AR (2005) Micro-social structural approaches to HIV prevention: a social ecological perspective. AIDS Care 17: 102-113.
35. Busza J, Walker D, Hairston A, Gable A, Pitter C, et al. (2012) Community-based approaches for prevention of mother to child transmission in resource-poor settings: a social ecological review.
36. Naar-King S, Arfken C, Frey M, Harris M, Secord E, et al. (2006) Psychosocial factors and treatment adherence in paediatric HIV/AIDS. AIDS Care 18: 621-628. (Pubitemid 44050520)
37. Chakrapani V, Newman PA, Singhal N, Jerajani J, Shunmugam M (2012) Willingness to participate in HIV vaccine trials among men who have sex with men in Chennai and Mumbai, India: a social ecological approach. PLoS One 7: e51080.
38. Parker R, Ehrhardt A (2001) Through an Ethnographic Lens: Ethnographic Methods, Comparative Analysis, and HIV/AIDS Research. AIDS Behav 5: 105-114. (Pubitemid 35364543)
39. Mack N, Woodsong C, MacQueen K, Guest G, Namey E (2005) Qualitative Research Methods: A Data Collector's Field Guide. Research Triangle Park, NC, USA: Family Health International.
40. Lewis J (2007) Analysing qualitative longitudinal research in evaluations. Social Policy and Society 6: 545.
41. van der Straten A, Stadler J, Hartmann M, Magee C, Seoka S, et al. (2013) Barriers and Facilitators to Oral and Topical (Vaginal Gel) PrEP Use in Johannesburg, South Africa: The VOICE-C Study. 8th International Conference on HIV Treatment and Prevention Adherence. Miami, FL.
42. Montgomery E, Stadler J, Hartmann M, Magee C, Magazi B, et al. (2013) Male partner roles and influence on women's use of HIV pre-exposure prophylaxis in Johannesburg; Sept 29-Oct 3, 2013; Barcelona, Spain.
43. Cleary S, Birch S, Chimbindi N, Silal S, McIntyre D (2013) Investigating the affordability of key health services in South Africa. Soc Sci Med 80: 37-46.
44. Corneli A, Wang M, Agot K, Ahmed K, Olang'o L, et al. (2013) The Association Between Risk Perception and Adherence in the FEM-PrEP Clinical Trial; 30 June-3 July 2013; Kuala Lumpur, Malaysia.
45. Saethre E, Stadler J (2013) Malicious Whites, Greedy Women, and Virtuous Volunteers. Med Anthropol Q 27: 103-120.
46. Crowcroft NS, McKenzie KJ (2013) Inoculating communities against vaccine scare stories. The Lancet infectious diseases 10.1016/S1473-3099(13)70131-2.
47. Nyblade L, Singh S, Ashburn K, Brady L, Olenja J (2011) "Once I begin to participate, people will run away from me": Understanding stigma as a barrier to HIV vaccine research participation in Kenya. Vaccine 29: 8924-8928.
48. Baeten JM, Grant R (2013) Use of Antiretrovirals for HIV Prevention: What Do We Know and What Don't We Know? Curr HIV/AIDS Rep 10.1007/s11904-013-0157-9: 1-10.
49. Guest G, Bunce A, Johnson L (2006) How Many Interviews Are Enough?: An Experiment with Data Saturation and Variability. Field Methods 18: 59-82.
50. Miles M, Huberman A (1994) Qualitative Data Analysis: An Expanded Sourcebook. Thousand Oaks, CA; London; New Delhi: Sage Publications, Inc.
51. Kincaid DL (2000) Social networks, ideation, and contraceptive behavior in Bangladesh: a longitudinal analysis. Soc Sci Med 50: 215-231.
52. Dearing JW, Smith DK, Larson RS, Estabrooks CA (2013) Designing for diffusion of a biomedical intervention. Am J Prev Med 44: S70-76.
53. Amico KR (2011) A situated-Information Motivation Behavioral Skills Model of Care Initiation and Maintenance (sIMB-CIM): an IMB model based approach to understanding and intervening in engagement in care for chronic medical conditions. J Health Psychol 10.1177/1359105311398727.
54. Remien RH, Mellins CA, Robbins RN, Kelsey R, Rowe J, et al. (2013) Masivukeni: Development of a Multimedia Based Antiretroviral Therapy Adherence Intervention for Counselors and Patients in South Africa. AIDS Behav: 1-13.
55. O'Laughlin KN, Wyatt MA, Kaaya S, Bangsberg DR, Ware NC (2012) How treatment partners help: social analysis of an African adherence support intervention. AIDS Behav 16: 1308-1315.
56. Knowlton AR, Yang C, Bohnert A, Wissow L, Chander G, et al. (2011) Informal care and reciprocity of support are associated with HAART adherence among men in Baltimore, MD, USA. AIDS Behav 15: 1429-1436.
57. Ware NC, Wyatt MA, Haberer JE, Baeten JM, Kintu A, et al. (2012) What's Love Got to Do With It? Explaining Adherence to Oral Antiretroviral Pre-Exposure Prophylaxis for HIV-Serodiscordant Couples. J Acquir Immune Defic Syndr 59: 463-468 410.1097/QAI.1090b1013e31824a31060b.
58. Haberer J, Psaros C, Baeten J, Katabira E, Tumwesigye E, et al. (2012) High adherence to oral PrEP is associated with lack of infections in an ancillary study of objective adherence monitoring and counseling among HIV discordant couples in Partners PrEP Study; March 5-8; Seattle, WA, USA.
59. Galárraga O, Genberg BL, Martin RA, Barton Laws M, Wilson IB (2013) Conditional Economic Incentives to Improve HIV Treatment Adherence: Literature Review and Theoretical Considerations. AIDS Behav 17: 2283-2292.
60. Abdool Karim SS (2011) Stigma impedes AIDS prevention. Nature 474: 29-31.